Author ORCID Identifier

https://orcid.org/0000-0003-2141-5267

Date of Graduation

8-2024

Document Type

Thesis (MS)

Program Affiliation

Quantitative Sciences

Degree Name

Masters of Science (MS)

Advisor/Committee Chair

Raghu Kalluri

Committee Member

Linghua Wang

Committee Member

Navin,Nicholas

Committee Member

Ken Chen

Committee Member

Fuentes Jr.,Natividad Roberto

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is highly malignant and exhibits aggressive progression patterns, resists conventional treatments, and poses significant challenges to patient survival, necessitating urgent research and development of novel therapeutic approaches. Understanding cancer-associated fibroblasts (CAF) metabolism reprogramming in PDAC tumor microenvironment (TME) may uncover novel therapeutic targets. Here, we used single cell and spatial transcriptomics to comprehensively characterize the TME content of human PDAC. We characterized CAFs metabotypes and a novel CAF population expressing DPEP1, COMP, CST1, which involved in glutathione metabolism, termed "gluCAFs” and was associated with poor clinical outcomes and advanced PDAC stages. We also validate the existence of DPEP1+CAF by multiplex immunofluorescence (IF) staining. The inhibition of KRASG12D and a combination therapy involving a Hedgehog inhibitor, Gemcitabine/Abraxane, and anti-CTLA4 can reprogram DPEP1+CAFs in the PDAC TME. Our study presents a high-resolution atlas of PDAC TME and highlights DPEP1+CAFs as a novel CAF subtype critical for PDAC progression and susceptibility to KRAS inhibitors and immunotherapy.

Keywords

Pancreatic ductal adenocarcinoma; Single cell RNA transcriptomics; Spatial transcriptomics; Tumor microenvironment; Cancer-associated fibroblast; Metabotype; Dipeptidase 1; Glutathione metabolic process

Available for download on Saturday, August 09, 2025

Share

COinS